Abstract Number: 1888 • 2019 ACR/ARP Annual Meeting
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Background/Purpose: The ability to accurately predict whether RA patients will flare following DMARD-tapering would open doors in clinical decision-making for achieving drug-free remission (DFR). Calprotectin…Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…Abstract Number: 1891 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis
Background/Purpose: Hydroxychloroquine (HCQ) has known immunomodulatory effects and mechanistic actions that may provide cardioprotective effects. To date, cardiovascular (CV) outcomes in elderly patients receiving HCQ…Abstract Number: 1892 • 2019 ACR/ARP Annual Meeting
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to…Abstract Number: 1893 • 2019 ACR/ARP Annual Meeting
Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
Background/Purpose: Chronic inflammation yields higher risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA). We recently reported that occult atherosclerosis burden on coronary…Abstract Number: 1894 • 2019 ACR/ARP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) compared…Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…Abstract Number: 1896 • 2019 ACR/ARP Annual Meeting
Breastfeeding in Women with Rheumatic Diseases
Background/Purpose: For many women, breastfeeding is a central aspect of motherhood, but many worry that their rheumatic disease or treatment will interfere. Fortunately, most anti-rheumatic…Abstract Number: 1897 • 2019 ACR/ARP Annual Meeting
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Background/Purpose: Although SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies…Abstract Number: 1898 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Background/Purpose: Rheumatoid arthritis (RA) during pregnancy is a risk factor for several adverse pregnancy and child outcomes. Studies have found higher incidences of neurological and…Abstract Number: 1899 • 2019 ACR/ARP Annual Meeting
sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia…Abstract Number: 1900 • 2019 ACR/ARP Annual Meeting
Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies
Background/Purpose: Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for…Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…Abstract Number: 1902 • 2019 ACR/ARP Annual Meeting
Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA
Background/Purpose: Primary Sjögren’s syndrome (pSS) is the second most frequent systemic autoimmune disease affecting 0.1% of the general population. No specific immunomodulatory drug has demonstrated…
ACR Meeting Abstracts